Investments in R&D Activities and Strong Product Sales Strengthen Companies' Financial Positions - Research Report on Alexion,

 Investments in R&D Activities and Strong Product Sales Strengthen Companies'
Financial Positions - Research Report on Alexion, Amgen, Vertex, Aegerion, and
                                    Acadia

PR Newswire

NEW YORK, August 2, 2013

NEW YORK, August 2, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Alexion
Pharmaceuticals, Inc. (NASDAQ: ALXN), Amgen Inc. (NASDAQ: AMGN), Vertex
Pharmaceuticals Incorporated (NASDAQ: VRTX), Aegerion Pharmaceuticals, Inc.
(NASDAQ: AEGR), and ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD). Today's
readers may access these reports free of charge - including full price
targets, industry analysis and analyst ratings - via the links below.

Alexion Pharmaceuticals, Inc. Research Report

On July 25, 2013, Alexion Pharmaceuticals Inc. (Alexion) reported its Q2 2013
financial results. The Company reported that its net products sales of Soliris
(eculizumab) were $370.1 million, an increase of 34.7% YoY, in Q2 2013. The
Company's GAAP net income for the quarter totaled $95.9 million or $0.48 per
diluted share, compared to $36.3 million or $0.18 per diluted share in Q2
2012. "In the second quarter, we continued our strong and ongoing global
performance with Soliris in PNH. In the early stages of our aHUS launch, we
were especially pleased to provide Soliris to a steadily growing number of
patients in the US and increasingly in Europe," said Leonard Bell, M.D., Chief
Executive Officer of Alexion. Bell added, "As we enter the second half of the
year, we will continue to develop our product portfolio toward supporting an
anticipated series of significant launches in new indications for Soliris and
new products over the next several years." Further, Alexion anticipates its
full-year 2013 revenue to range between $1.52 billion and $1.53 billion,
followed by non-GAAP EPS range of $2.97 and $3.02. The Full Research Report on
Alexion Pharmaceuticals, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/4619_ALXN]

Amgen Inc. Research Report

On July 30, 2013, Amgen Inc. (Amgen) reported its Q2 2013 financial results.
The Company posted a revenue growth of 4.5% YoY to $4.7 million, followed by
an adjusted EPS increase of 3.3% YoY to $1.89, in Q2 2013. Meanwhile, adjusted
net income grew 0.8% YoY to $1.4 million during the quarter. "We saw solid
product trends during the second quarter and are carrying good momentum into
the second half," said Robert A. Bradway, Chairman and Chief Executive Officer
at Amgen. "We continue to make excellent progress with our pipeline of
innovative molecules and look forward to multiple data readouts in 2014,
including pivotal Phase 3 data for our cholesterol-lowering agent, AMG 145, in
the first quarter." For full-year 2013, the Company anticipates total revenues
to range between $17.8 billion and $18.2 billion and adjusted EPS to be in the
range of $7.30 to $7.45. The Full Research Report on Amgen Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/e96b_AMGN]

Vertex Pharmaceuticals Incorporated Research Report

On July 29, 2013, Vertex Pharmaceuticals Inc. (Vertex) reported its Q2 2013
financial results. The Company's revenues totaled $310.8 million during the
quarter, down compared to $418.3 million in Q2 2012. GAAP net loss was $57.2
million or $0.26 per share in Q2 2013, compared to net loss of $64.9 million
or $0.31 per diluted share in Q2 2012. "Entering the second half of 2013, we
continue to progress key programs in cystic fibrosis, hepatitis C and
rheumatoid arthritis and have strengthened our financial position to support
continued investment in our business," said Jeffrey Leiden, M.D., Ph.D.,
Chairman, President and Chief Executive Officer of Vertex. "Our progress in
the first half of the year was marked by the initiation of a Phase 3 program
in CF for people with the most common form of the disease, continued progress
in bringing KALYDECO to people with CF around the world and the initiation of
all-oral studies for VX-135 in hepatitis C." Further, Vertex updated its
full-year 2013 revenues guidance to a range between $1.1 billion and $1.2
billion. The Full Research Report on Vertex Pharmaceuticals Incorporated -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/e696_VRTX]

Aegerion Pharmaceuticals, Inc. Research Report

On July 30, 2013, Aegerion Pharmaceuticals, Inc. (Aegerion) reported its Q2
2013 financial results. Net loss for the quarter was $18.9 million, or $0.66
per share, compared with net loss of $13.9 million, or $0.63 per share, in Q2
2012. Aegerion's R&D expenses increased to $7.6 million in Q2 2013 from $5.4
million in Q2 2012, driven by increased employee costs related to the
Company's medical affairs and international regulatory activities, as well as
increased clinical development expenses. "We continue to execute on launch,
advancing early market uptake, and we see significant room for continued
growth as we calibrate our activities surrounding the launch of JUXTAPID in
the U.S.," said Marc D. Beer, Chief Executive Officer. The Full Research
Report on Aegerion Pharmaceuticals, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.analystscorner.com/r/full_research_report/a3f6_AEGR]

ACADIA Pharmaceuticals, Inc. Research Report

On July 30, 2013, Acadia Pharmaceuticals Inc. (Acadia) announced that it will
release its Q2 2013 unaudited financial results on August 6, 2013, after the
US financial markets close. Acadia's management will host a conference call
and webcast on the same day at 5:00 p.m. ET, to discuss its financial results
and development programs. The conference call will be webcast live on ACADIA's
website and will be archived there until August 20, 2013. The Full Research
Report on ACADIA Pharmaceuticals, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.analystscorner.com/r/full_research_report/3eb7_ACAD]

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    making mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Analysts' Corner

Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.